Annals of Oncology· @Annals_Oncology · X·· 2 天前评分90
正文 · 原文
📢 #ESMO26 concomitant paper - Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial.
🔗https://shorturl.at/AsvoB
@LoiSher
4056 浏览 · 16 赞 · 6 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Annals of Oncology · x.com